Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Anticancer Res. 2020 Mar;40(3):1613-1618. doi: 10.21873/anticanres.14109.
BACKGROUND/AIM: To evaluate the efficacy and toxicity of paclitaxel, gemcitabine, and cisplatin (TGP) as second-line treatment for advanced urothelial carcinoma (UC).
This study comprised advanced UC progressed after first-line cisplatin-based chemotherapy. Advanced UC was defined as a non-resectable (T4b, any N or any T, or N2-3) or metastatic disease. Twenty-one patients were included in this study. TGP was administered every 3 weeks. The primary endpoint was objective response rate (ORR); the secondary end points were progression-free survival (PFS), overall survival (OS), and toxicity.
The ORR with TGP was 23.8%; the median PFS and OS were 4 and 8.4 months, respectively. The primary side effect was myelosuppression. Grade 3-4 neutropenia and thrombocytopenia were observed in 71.4% and 42.9%, respectively. There were no toxic deaths.
TGP is moderately effective and tolerable as second-line chemotherapy for patients with UC.
背景/目的：评估紫杉醇、吉西他滨和顺铂（TGP）作为二线治疗晚期尿路上皮癌（UC）的疗效和毒性。
本研究纳入了一线顺铂为基础的化疗后进展的晚期 UC 患者。晚期 UC 定义为不可切除（T4b，任何 N 或任何 T，或 N2-3）或转移性疾病。本研究纳入了 21 例患者。TGP 每 3 周给药一次。主要终点是客观缓解率（ORR）；次要终点是无进展生存期（PFS）、总生存期（OS）和毒性。
TGP 的 ORR 为 23.8%；中位 PFS 和 OS 分别为 4 个月和 8.4 个月。主要的副作用是骨髓抑制。71.4%的患者出现 3-4 级中性粒细胞减少症，42.9%的患者出现 3-4 级血小板减少症。无治疗相关死亡。
TGP 作为二线化疗药物，对 UC 患者具有一定的疗效和可耐受性。
